12:00 AM
Jul 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AVN-211: Phase IIb started

Avineuro began a Russian Phase IIb trial to evaluate 4 and 8 mg AVN-211 once daily for 6 weeks in 80 patients with schizophrenia in a state of a partial...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >